|
02 Mar 2019 |
Halozyme Announces FDA Approval Of Herceptin Hylecta
|
|
02 Mar 2019 |
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis
|
|
01 Mar 2019 |
ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
|
|
28 Feb 2019 |
Fosun Pharma Has Opened a New Era for Biosimilar in China Henlius Receives NMPA Approval for Its First Product HLX01
|
|
27 Feb 2019 |
Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
|
|
27 Feb 2019 |
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
|
|
27 Feb 2019 |
TG Therapeutics Announces Initiation of Phase I First-in-Human Clinical Trial of its Anti-CD47/CD19 Bispecific Antibody, TG-1801, in Patients with Relapsed or Refractory B-cell Lymphoma
|
|
27 Feb 2019 |
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
|
|
25 Feb 2019 |
Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab
|
|
25 Feb 2019 |
Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
|
|
24 Feb 2019 |
Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab
|
|
24 Feb 2019 |
FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
|
21 Feb 2019 |
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
|
|
21 Feb 2019 |
Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150
|
|
20 Feb 2019 |
Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors
|
|
20 Feb 2019 |
Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045
|
|
20 Feb 2019 |
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
|
|
20 Feb 2019 |
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer (SCLC)
|
|
20 Feb 2019 |
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
|
|
20 Feb 2019 |
Pfizer Receives European Approval for ZIRABEV (bevacizumab), a Biosimilar to Avastin
|
|
20 Feb 2019 |
Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
|
|
20 Feb 2019 |
Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody
|
|
19 Feb 2019 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
|
|
19 Feb 2019 |
FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma
|
|
18 Feb 2019 |
Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019
|
